The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

Zegfrovy is designed to target a broad range of EGFR mutations while maintaining selectivity over wild-type EGFR.

The approval of sunvozertinib, an oral irreversible EGFR inhibitor, was supported by data from the WU-KONG1B trial (ClinicalTrials.gov Identifier: NCT03974022 ). The primary efficacy population ...

DNMT3A mutations emerged as potential biomarkers for enhanced immunotherapy benefit in non-small cell lung cancer.

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...

Our findings highlight the molecular diversity and diagnostic challenges of HER2-mutated NSCLC in underrepresented ...

By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

An investigational oral targeted therapy, zipalertinib (CLN-081), demonstrated meaningful tumor responses and a manageable ...

During June, investigators reported new data that has advanced the treatment landscape for lung cancer, including new FDA ...

A new treatment option, Datroway (datopotamab deruxtecan or Dato-DXd), is now available for people with non-small cell lung ...